Claims for Patent: 10,342,790

Summary for Patent: 10,342,790

Title:	Use of ceranib-2 in the treatment of lung cancer
Abstract:	The present invention relates to the use of ceranib-2 molecule in the treatment of lung cancer and breast cancer. At the same time, the present invention also describes the in vitro studies made by the inventors in this direction.
Inventor(s):	Kutlu; Hatice Mehtap (Eskisehir, TR), Kus; Gokhan (Eskisehir, TR)
Assignee:	ANADOLU UNIVERSITESI REKTORLUGU (Eskisehir, TR)
Application Number:	15/899,520
Patent Claims:	1. A method for treating lung cancer, or eliminating the symptoms resulting from lung cancer, the method comprising using ceranib-2. 2. The method of claim 1, wherein the lung cancer is small cell lung cancer, lung cancer except small cell lung cancer, adeno cancer, squamous celled cancer or large celled cancer. 3. The method of claim 1, wherein ceranib-2 is used together with at least one other antineoplastic agent. 4. The method of claim 3, wherein the other antineoplastic agent is selected from a group comprising cyclo-phosphamide, iphosphamide, temozolomide, capecitabine, 5 fluorouracil, methotrexate, gemcitabine, pemetrexed, mitomycin, bleomycin, epirubicin, doxorubicin, etoposide, paclitaxel, irinotecan, docetaxel, vincristine, carboplatin, cisplatin, oxaliplatin, bevacizumab, cetuximab, gefitinib, imatinib, trastuzumab, denosumab, rituximab, sunitinib, zoledronat, abirateron, anastrozole, bicalutamide, exemestane, goserelin, medroxy-progesterone, octreotide, tamoxifen, bendamustine, carmustine, chlorambucil, lomustine, melphalan, procarbazine, streptozosin, fludarabine, raltitrexed, actinomycin D, dactinomycin, doxorubicin, mitoxantrone, eribulin, topotecan, vinblastine, vinorelbine, afatinib, aflibercept, crizotinib, dabrafenib, interferon, ipilimumab, lapatinib, nivolumab, panitumumab, pembrolizumab, pertuzumab, sorafenib, trastuzumab emtansin, temsorilimus, vemurafenib, ibandronic acid, pamidronate, bexarotan, buserelin, cyproterone, degarelix, folinic acid, fulvestrant, lanreotide, lenalidomide, letrozole, leuproreline, megestrol, mesna, thalidomide or from the double or triple combinations of them. 5. The method of claim 1, wherein ceranib-2 is used at a dose between 1 .mu.g/kg and 1 g/kg.

Details for Patent 10,342,790

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2037-02-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2037-02-20
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2037-02-20
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2037-02-20
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2037-02-20
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2037-02-20
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2037-02-20